Fitoterapia zespołu poboreliozowego

• Autorzy: Figura P.

Warianty tytułu

EN

Phytotherapy of posttreatment Lyme disease syndrome

• Języki publikacji: PL

Abstrakty

PL

Uznanym standardem leczenia boreliozy jest antybiotykoterapia, zarówno w monoterapii, jak i łączona. We wczesnej fazie choroby wykazują one umiarkowaną skuteczność. W przypadku nawet 1/3 chorych poddanych leczeniu, w dalszym ciągu manifestują się różne objawy określane jako zespół poboreliozowy (PTLDS). Za przyczynę PTLDS uważa się uszkodzenia patofizjologiczne pozostałe po chorobie lub przewlekła infekcja krętkami B. burfgerdori (Bb) sensu lato w formach owalnych oraz chronione przez biofilm. Zwykle stosowane przy boreliozie antybiotyki nie przynoszą efektów przy PTLDS, także przy wydłużonym czasie leczenia. Zasadne zatem wydaje się zwrócenie w kierunku poszukiwania nowych związków mogących wspomóc leczenie. Interesującym kierunkiem zdaje się badanie związków fitochemicznych i ekstraktów roślinnych. Przegląd badań wskazuje, iż niektóre z nich wykazują wysoką efektywność wobec Bb w monoterapii i terapii kombinowanej z antybiotykami, m.in. ekstrakt ze stewii, bajkalina. Omówiona zostanie także fitoterapia Buhnera.

EN

The recognized standard in Lyme disease treatment is antibiotic therapy, both in monotherapy or in combination. This approach is fairly effective in the early stages of the disease. In up to 1/3 of the patients treated, Lyme disease symptoms remain; which is diagnosed as PTLDS. The cause of PTLDS is considered to be pathophysiological damage after the disease or a chronic infection of B. burfgerdori (Bb) sensu lato remaining in oval forms and protected by biofilm. Standard antibiotic Lyme treatment is ineffective in PTLDS, as well as extended treatments. Therefore, it seems reasonable to look for new compounds that can aid treatment. An interesting direction seems to be the study of phytochemical compounds and plant extracts. A review of the studies indicates that some of them, such as Stevia extract, Baikalin are highly effective against Bb in monotherapy and in combination therapy with antibiotics. Buhner's phytotherapy will also be discussed.

Słowa kluczowe

PL

choroby czlowieka; borelioza; ziololecznictwo; zespol poboreliozowy; leczenie; rosliny lecznicze; rdestowiec japonski zob.rdest ostrokonczysty; rdest ostrokonczysty; brodziuszka wiechowata; Andrographis paniculata; witania ospala; tarczyca bajkalska; czepota puszysta; eleuterokok kolczasty; gou teng

• Wydawca: -
• Czasopismo: Herbalism
• Rocznik: 2017
• Numer: 1[3]
• Opis fizyczny: s.137-149,bibliogr.

Twórcy

autor

Figura P.

• Uniwersytet Medyczny w Poznaniu, ul.Fredry 10, 61-701 Poznań

Bibliografia

• (1) Wasiluk A., Zalewska-Szajda B., Waszkiewicz N., Kępka A., Szajda D.S., Wojewódzka- Żeleźniakowicz M., Ładny J.R., Pancewocz S., Zwierz Z.W., Zwierz K., Lyme disease: etiology, pathogenesis, clinical courses, diagnostics and treatment, Progress in Health Sciences, 2011, 1(2), s. 179-186.
• (2) Rauter C., Hartung T., Prevalence of Borrelia burgdorferi Sensu Lato Genospecies in Ixodes ricinus Ticks in Europe: a Metaanalysis, Applied and Environmental Microbiology, 2005, 71(11), s. 7203-7216.
• (3) Stan sanitarny kraju w roku 2015, Główny Inspektorat Sanitarny
• (4) Dissemination of GP consultations for erythema migrans in the Netherlands from 1994 to 2014 [source: RIVM],
• (5) Sykes R.A., Makiello P., An estimate of Lyme borreliosis incidence in Western Europe, Journal of Public Health (Oxford), 2017, 39(1), s. 74-81.
• (6) Centers for Disease Control and Prevention, Reported cases of Lyme disease by state or locality 2005-20151"., 2016, https://www.cdc.gov/lyme/stats/tables.html [Akces: 29.05.2017],
• (7) Centers for Disease Control and Prevention, How many people get Lyme disease?, 2015, https://www.cdc.gov/lyme/stats/humancases.html [Akces: 29.05.2017],
• (8) Smith R.P., Schoen R.T., Rahn D.W., Sikand V.K., Nowakowski J., Parenti D.L., Holman M.S., Persing D.H., Steere A.C., Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans, Annals of Internal Medicine, 2002,136, s. 421-428.
• (9) Cook M.J., Puri B.K., Commercial test kits for detection of Lyme borreliosis: a meta-analysis of test accuracy, International Journal of General Medicine, 2016,9, s. 427-440.
• (10) Flisiak R., Pancewicz S., Diagnostyka i leczenie Boreliozy z Lyme. ZaleceniePolskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych, Przegląd Epidemiologiczny, 2008, 62(1), s. 193-199.
• (11) Zajkowska J., Lewczuk P., Strle F., Stanek G., Lyme Borreliosis: From Pathogenesis to Diagnosis and Treatment, Clinical and Developmental Immunology, 2012, Article ID 23165.
• (12) Taylor R.S., Simpson I.N., Review of treatment options for lyme borreliosis, Journal of Chemoteraphy, 2005,2, s. 3-16.
• (13) Wormser G.P., Ramanathan R., Nowakowski J., McKenna D., Holmgren D., Visintainer P., Dornbush R., Singh B., Nadelman R.B., Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial, Annals of Internal Medicine, 2003, 138(9), s. 697-704.
• (14) Stupica D., Daša Stupica Lusa L., Ružič-Sabljić E., Cerar T., Strle F., Treatment of erythema migrans with doxycycline for 10 days versus 15 days, Clinical Infectious Disesases: an official publication of the Infectious Diseases Society of America, 2012, 55(3), s. 343-350.
• (15) Bremell D., Dotevall L., Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension, European Journal of Neurology, 2014,21(9), s. 1162-1167.
• (16) Borg R., Dotevall L., Hagberg L., Mareaspin V., Lotric-Furlan S., Cimperman J., Strale F., Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis, Scandinavian Journal of Infectious Diseases, 2005, 37(6-7), s. 449-454.
• (17) Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., Krause P.J., Bakken J.S., Strle F., Stanek G., Bockenstedt L., Fish D., Dumler J.S., Nadelman R.B., The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious, Diseases Society of America. Clinical Infectious Diseases, 2006, 43(9), s. 1089-1134.
• (18) Aueott J.N., Rebman A.W., Crowder L.A., Kortte K.B., Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?, Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2013,22(1), s. 75-84.
• (19) Cameron D., i wsp., Evidence-based guidelines for the management of Lyme disease, Expert review of anti-infecive therapy, 2004, 2(1), s. 1-13.
• (20) Lantos P.M., Chronic Lyme disease: the controversies and the science, Expert review of anti-infecive therapy, 2011, 9(7), s. 787-797.
• (21) Wasiluk A., Zalewska-Szajda B., Waszkiewicz N., Kępka A., Szajda D.S., Wojewódzka- Żeleźniakowicz M., Ładny J.R., Pancewocz S., Zwierz Z.W., Zwierz K., Lyme disease: etiology, pathogenesis, clinical courses, diagnostics and treatment, Progress in Health Sciences, 2011,1(2), s. 179-186.
• (22) Steere A.C., Angelis S.M., Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthrithis, Arthritis and rheumatism, 2006,54(10), s. 3079-3086.
• (23) Aueott J.N., Rebman A.W., Crowder L.A., Kortte K.B., Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?, Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2013, 22(1), s. 75-84.
• (24) Chandra A., Wormser G.R, Marques A.R., Latov N., Alaedini A., Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome, Clinical and vaccine immunology: CVI, 2011, 18(15), s. 767-771.
• (25) Schutzer S.E., Angel T.E., Liu T., Schepmoes A.A., Clauss T.R., Adkins J.N., Camp II D.G., Holland B.K., Berdquist J., Coyle P.K., Smith R.D., Fallon B.A., Natelson B.H., Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome, PLoS One, 2011,6(2), s. 17287.
• (26) Ścieszka J., Dąbek J., Cieślik P., Post-Lyme disease syndrome, Reumatologia, 2015, 53(1), s. 46-48.
• (27) Sharma B., Brown A.V., Matluck N.E., Hu L.T., Lewis K., Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells, Antimicrobial Agents and Chemotherapy, 2015, 59(8), s. 4616-4624.
• (28) Lantos P.M., Auwaerter P.G., Wormser G.P., A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease, Clinical Infectious Disesases: an official publication of the Infectious Diseases Society of America, 2014, 58(5), s. 663-671.
• (29) Brorson Ø., Brorson S.H., Scythes J., MacAllister J., Wier A., Margulis L., Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic Tigecydine, PNAS, 2009, 106(44), s. 18656-18661.
• (30) Sapi E., Kaur N., Anyanwu S., Luecke D., Datar A., Patel S., Rossi M., Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi, Infection and Drug Resistance, 2011,4, s. 97-113.
• (31) Sapi E., Balasubramanian K., Poruri A., Maghsoudlou J.S., Socarras K.M., Timmaraju A.V., Filush K.R., Gupta K., Shaikh S., Theophilus P.A.S., Luecke D.F., MacDonald A., Zelger B., Evidence ofin Vivo Existence of Borrelia Biofilm in Borrelial Lymphocyto- mas, European Journal of Microbiolgy & Immunology, 2016, 6(1), s. 9-24.
• (32) Bunikis I., i wsp., An RND-Type Efflux System in Borrelia burgdorferi Is Involved in Virulence and Resistance to Antimicrobial Compounds. Wessels MR, ed. PLoS Pathogens. 2008,4(2), s. 1000009.
• (33) Greene N.P., Hinchliffe P., Crow A., Ababou A., Hughes C., Koronakis V., Structure of an atypical periplasmic adaptor from a multidrug efflux pump of the spirochete Borrelia burgdorferi, FEBS Letters, 2013, 587(18), s. 2984-2988.
• (34) Song T., Duperthuy M., Wai S.N., Sub-Optimal Treatment of Bacterial Biofilms, Antibiotics, 2016, 5(2), s. 23.
• (35) Klempner M.S., Baker P.J., Shapiro E.D., Marques A., Dattwyler R.J., Halperin J.J., Wormser G.P.,Treatment trials for post-lyme disease symptoms revisited, The American Journal of Medicine, 2013,126(8), s. 665-669.
• (36) Goc A., Niedzwiecki A., Rath M., In vitro evaluation of antibacterial activity of phytochemicals and micronutrients against Borrelia burgdorferi and Borrelia garinii, Journal of Applied Microbiology, 2015, 119(6), s. 1561-1572.
• (37) Goc A., Rath M., The anti-borreliae efficacy of phytochemicals and micronutrients: an update, Therapeutic Advances in Infectious Disease, 2016, 3(3-4), s. 75-82.
• (38) Theophilus P.A., Victoria M.J., Socarras K.M., Filush K.R., Gupta K, Luecke D.F., Sapi E., Effectiveness of Stevia Rebaudiana Whole Leaf Extract Against the Various Morphological Forms of Borrelia Burgdorferi in Vitro, European Journal of Microbiology & Immunology, 2015, 5(4), s. 268-280.
• (39) European Food Safety Authority (EFSA), Scientific Opinion on the safety of steviol glycosides for the proposed uses as a food additive, EFSA Journal, 2010, 8(4): 1537, s. 1-84.
• (40) Siddique A.B., Rahman S.M.M., Hossain M.A., Rashid M.A., Phytochemical screening and comparative antimicrobial potential of different extracts of Stevia rebaudiana Bertoni leaves, Asian Pacific Journal of Tropical Disease, 2014,4, s. 275-280.
• (41) Buhner S.H., Healing Lyme: Natural Healing and Prevention of Lyme Borreliosis and Its Coinfections, Wyd. Raven Press, Silver city 2016.
• (42) Różański H., Rdestowce - Reynoutria (Fallopia), 2007, http://www.luskiewnik.pl/au- toimmunologia/new-page-7.htm [Akces: 29.05.2017].
• (43) Ghanim H., Abuaysheh S., Korzeniewski K., Patnaik P., Marumganti A., Chaudhuri A., Dandona P., An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol, The Journal of Clinical Endocrinology and Metabolism, 2010, 95(9): El-8.
• (44) Kowalski J., Samojedny A., Paul M., Pietsz G., Wilczok T., Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-lbeta and tumor necrosis fac- tor-alpha genes in J774.2 macrophages, Pharmacological Reports: PR, 2005, 57(3), s. 390-394.
• (45) Li Y.B., Ying Bo Li, Lin Z., Zhang Z., Wang M.W., Zhang H., Zhang Q.W., Lee S.M., Wang Y., Hoi P.M., Protective, antioxidative and antiapoptotic effects of 2-methoxy- 6-acetyl-7-methyljuglone from Polygonum cuspidatum in PC 12 cells, Planta Medica, 2011,77(4), s. 354-361.
• (46) Jantan I., Ahmad W., Bukhari S.N.A., Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials, Frontiers in Plant Science, 2015, 6, s. 655.
• (47) Amaryan G., Astvatsatryan V., Gabrielyan E., Panossian A., Panosyan V., Wikman G., Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard-a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail, and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. Phytomedicine, International Journal of Phythoherapy and Phytopharmacology, 2003,10(4), s. 271-285.
• (48) Chao W.W., Lin B.F., Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian), Chinese Medicine, 2010, 5, s. 1-7.
• (49) Pan Y., Abd-Rashid B.A., Ismail Z., Ismail R., Mak J.W., Pook P.C., Er H.M., Ong C.E., In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19), Journal of Ethnopharmacology, 2011, 133(2), s. 881-887.
• (50) Trivedi M.K., Mondal S.Ch., Gangwar M., Jana S., Effect of a Novel Ashwagandha-based Herbomineral Formulation on Pro-inflammatory Cytokines Expression in
• Mouse Splenocyte Cells, A Potential Immunomodulator. Pharmacognosy Magazine, 2017;13(1), s. 90-94.
• (51) Tohda C, Kuboyama T., Komatsu K., Search for natural products related to regeneration of the neuronal network, Neuro-Signals, 2005, 14(1-2), s. 34-45.
• (52) Jeon S.J., Rhee S.Y., Seo J.E., Bak H.R., Lee S.H., Ryu J.H., Cheong J.H., Shin C.Y., Kim G.H., Lee Y.S., Ko K.H., Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture, Neuroscience Reaserch, 2011,69(3), s. 214-222.
• (53) Qiu J., Niu X., Dong J., Wang D., Wang J., Li H., Luo M., Li S., Feng H., Deng X., Baicalin protects mice from Staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α -hemolysin, Journal of Infectious Diseases, 2012,206(2), s. 292-301.
• (54) Yun B.Y., Zhou L., Xie K.P., Wang Y.J., Xie M.J., Antibacterial activity and mechanism ofbaicalein. Yao Xue Xue Bao, Acta Pharmaceutica Sinica, 2012,47(12), s. 1587-1592.
• (55) Duan D.D., Wang K.X., Zhou Y.Z., Qin X.M., Gao L., Du G.H., Baicalein exerts beneficial effects in D-galactose induced aging rats through attenuation of inflammation and metabolic dysfunction. Rejuvenation Research, 2017, [Epub ahead of print].
• (56) European Medicines Agency, 2015, http://www.ema.europa.eu/docs/en_GB/doc- ument_library/Herbal_-_HMPC_assessment_report/2016/01/WC500200126.pdf [Akces: 29.05.2017],
• (57) Rojas-Duran R., González-Aspajo G., Ruiz-Martel C., Bourdy G., Doroteo-Ortega V.H., Alban-Castillo J., Robert G., Auberger P., Deharo E., Anti-inflammatory activity of Mitraphylline isolated from Uncaria tomentosa bark, Journal of Ethnopharmacology, 2012, 143(3), s. 801-804.
• (58) Priyanka A.S., Uieophilus M.S., In Vitro Effect of Peruvian Antimicrobial Agents on Borrelia burgdorferi. http://www.nutramedix.ee/Nutramedix-Priyanka.pdf [Akces 29.05.2017].
• (59) Ma B., Zhang Q., Liu Y., Li J., Xu Q., Li X., Yang X., Yao D., Sun J., Cui G., Ying H., Simultaneous determination of Eleutheroside B and Eleutheroside E in rat plasma by high performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study, Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 2013,917-918, s. 84-92.
• (60) Huang L., Zhao H., Huang B., Zheng C., Peng W., Qin L., Acanthopanax senticosus: review of botany, chemistry and pharmacology, Die Pharmazie, 2011, 66(2), s. 83-97.
• (61) Hartz A.J., Bentler S., Noyes R., Hoehns J., Logemann C., Sinift S., Butani Y., Wang W., Brake K., Ernst M., Kautzman H., Randomized controlled trial of Siberian ginseng for chronic fatigue, Psychological Medicine, 2004, 34(1), s. 51-61.
• (62) Zhang N., Crombruggen K. van, Holtappels G., Bachert C., A Herbal Composition of Scutellaria baicalensis and Eleutherococcus senticosus Shows Potent Anti-Inflamma- tory Effects in an Ex Vivo Human Mucosal Tissue Model, Evidence-Based Comple- menttary and Alternative Medicine, 2012,20, s. 1-9.
• (63) Song Y., Qu R., Zhu S., Zhang R., Ma S., Rhynchophylline attenuates LPS-induced pro-inflammatory responses through down-regulation of MAPK/NF-kB signaling pathways in primary microglia, Phytotherapy Research, 2012,26(10), s. 1528-1533.